Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials

• Egile Nagusiak: Kristian Reich (Egilea), Diamant Thaçi (Egilea), Georg Stingl (Egilea), Jens Strodl Andersen (Egilea), Line Conradsen Hiort (Egilea), Michala Oron Lexner (Egilea), David Winkler (Egilea), Carle Paul (Egilea)
• Formatua: Liburua
• Argitaratua: Medical Journals Sweden, 2022-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Brodalumab is approved for treatment of moderate-to-severe plaque psoriasis. Here, we assess the safety profile of brodalumab using pooled safety data from 5 phase II/III trials of brodalumab 140 mg or 210 mg. In total, 4,464 patients received brodalumab, representing 8,891.6 patient-years of exposu...